Literature DB >> 9766867

Stereoselective binding of ketoprofen enantiomers to human serum albumin studied by high-performance liquid affinity chromatography.

Z D Zhivkova1, V N Russeva.   

Abstract

A chiral stationary phase based on immobilized human serum albumin (HSA) was used to study the stereoselective binding of ketoprofen enantiomers by means of high-performance liquid affinity chromatography. The technique of zonal elution was applied together with a novel mathematical approach describing attachment to more than one type of binding site. Phenylbutazon (PBZ) and diazepam (DAZ) were used as markers for the major believed binding regions on HSA. Both R- and S-ketoprofen (KTR and KTS) display high affinity to the primary PBZ- and DAZ-binding sites and low-affinity to the secondary DAZ sites. The binding to high-affinity regions is accepted to be a stepwise process initiated by the binding to the primary DAZ sites and followed by the attachment to the primary PBZ sites. The chiral recognition is attributed to the high-affinity PBZ-binding sites and to the low-affinity DAZ-binding sites.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766867     DOI: 10.1016/s0378-4347(98)00211-4

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  3 in total

Review 1.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Stereoselective binding of mexiletine and ketoprofen enantiomers with human serum albumin domains.

Authors:  Da Shi; Yin-xiu Jin; Yi-hong Tang; Hai-hong Hu; Si-yun Xu; Lu-shan Yu; Hui-di Jiang; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

3.  Organism-specific differences in the binding of ketoprofen to serum albumin.

Authors:  Mateusz P Czub; Alan J Stewart; Ivan G Shabalin; Wladek Minor
Journal:  IUCrJ       Date:  2022-07-16       Impact factor: 5.588

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.